Investors Purchase High Volume of Call Options on Alphatec (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC) was the recipient of some unusual options trading on Friday. Stock traders bought 2,902 call options on the company. This represents an increase of 92% compared to the typical daily volume of 1,511 call options.

Insider Activity at Alphatec

In related news, CEO Patrick Miles sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the completion of the sale, the chief executive officer now directly owns 6,152,544 shares of the company’s stock, valued at approximately $74,015,104.32. This trade represents a 0.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the completion of the transaction, the executive vice president now directly owns 502,311 shares in the company, valued at $5,379,750.81. The trade was a 10.40 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 337,321 shares of company stock worth $3,828,060. Insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Large investors have recently bought and sold shares of the business. R Squared Ltd acquired a new position in shares of Alphatec during the 4th quarter worth about $29,000. Comerica Bank lifted its stake in Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 973.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 4,234 shares in the last quarter. Quarry LP increased its stake in Alphatec by 79.2% in the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after purchasing an additional 2,375 shares during the last quarter. Finally, Newton One Investments LLC acquired a new stake in Alphatec during the fourth quarter worth approximately $50,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Shares of ATEC opened at $9.29 on Friday. Alphatec has a 1 year low of $4.88 and a 1 year high of $14.88. The stock has a market capitalization of $1.34 billion, a PE ratio of -7.26 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The stock has a 50-day simple moving average of $10.95 and a 200-day simple moving average of $8.70.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. On average, analysts predict that Alphatec will post -1.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Piper Sandler boosted their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of Alphatec in a report on Thursday, February 27th. Finally, Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.